Next-generation approaches currently prioritize covalent EZH2 inhibitors (e.g., MS1943) and dual EZH2/HDAC degraders to overcome compensatory resistance mechanisms, although tumor-selective delivery remains a critical translational barrier. This evidence concerns the gene HDAC9 and neoplasm.